I would like to highlight something to the committee, or perhaps even make a correction. It was stated by one of the witnesses that under the NHP regulations, there was no assessment done of these products. I want to assure you that this is not correct.
In fact, there's a full assessment done, a pre-market assessment, which would not be done in any other country where these products are regulated as food. The fact that they are regulated as drugs gives these products a stricter or more complete regulatory oversight. The safety, quality, and efficacy are all looked at prior to a licence being issued.
As well, the surveillance mechanism was referred to. Yes, we do continue to look at the adverse reaction reports, and we promote the consideration of those reports by medical professionals and others through mechanisms that I mentioned before. We will continue to do that.